E.R. has received honoraria from Eli Lilly, Novartis and Seagen; has received travel support from Gilead, Mundipharma, Novartis, Pfizer and Roche; and research funding from Gilead, Menarini and MSD. F.A. has acted as a consultant and/or adviser of AstraZeneca, Daiichi–Sankyo, Lilly, Novartis, Pfizer, Relay Tx and Roche; has received travel support from Astrazeneca, GlaxoSmithKline, Lilly, Novartis and Roche; and has received research funding from AstraZeneca, Daiichi, Eli Lilly, Novartis, Pfizer and Roche.